Worldwide VP 16 or vinblastine/ifosfamide cisplatin (VIP) is established as the most frequently used second line therapy for germ cell cancer with 23% of patients achieving durable complete remission (Einhorn 1992, ASCP abst 599). Several authors have developed regimens for poor risk patients giving cisplatin more frequently that q21 (eg. BOP, POMP, HIPE, BOP/VIP) though none have been as extensively tested as second line therapy as VIP. To investigate this issue 46 relapse patients have been treated with a methotrexate, bleomycin, oncovin, cisplatin (MBOP) regimen developed from that of Wettlaufer et al. 1984;53:203. Treatments were given q7 for 4 weeks and then alternating 2 weeks on, 2 weeks off for a total of 8–10 treatments. 18/46 (39%) remain continuously relapse free (CRF) and 2 in stable disease for 2 or more years (11 of 31 (46%) BEP and 7 of 15 (46%) Carboplatin failures were CRF). The majority of patients failing this treatment proceeded to VIP, and more recently treated patients have received high dose treatment as consolidation (carboplatin 1200mg/m 2 etoposide 1400–1500mg/m 2 , ifosfamide 6g.m 2 ) with stem cell rescue. 9 of 27 (33%) patients undergoing 3rd line treatment achieved subsequent durable complete remission status, including 6 of 9 consolidated with high dose treatment. Currently 27 of 46 (59%) remain disease free,+2 static disease. With serious myelotoxicity less significant in BOP than VIP treated patients, and the recent failure of BOP/VIP as first line to improve over BEP, the results justify further exploration of this approach.